Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
- PMID: 25829189
- DOI: 10.4081/reumatismo.2014.799
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Abstract
Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
